Johnson & Johnson reported second-quarter earnings for 2025 that exceeded Wall Street expectations, with adjusted earnings per share (EPS) of $2.77 surpassing estimates of $2.68 and revenue of $23.74 billion beating the forecasted $22.84 billion. Despite Stelara's revenue of $1.65 billion falling short of the estimated $1.81 billion, Darzalex generated $3.54 billion, exceeding projections. The company raised its full-year sales outlook to a range of $93.2 billion to $93.6 billion, up from a prior estimate of $91 billion to $91.8 billion, and adjusted EPS guidance to $10.80 to $10.90, above the previous $10.50 to $10.70 range. Operational sales growth was driven by strong performance in both the Innovative Medicine and MedTech segments, with U.S. sales increasing 8% year-over-year. Favorable foreign exchange rates also contributed to the outlook revision. Johnson & Johnson's shares rose in pre-market trading following the announcement. Separately, Coca-Cola reported its second-quarter 2025 earnings with adjusted EPS of $0.87, beating the estimate of $0.83, while revenue was slightly below expectations at $12.50 billion versus $12.55 billion forecast. Organic revenue grew 5% year-over-year, supported by a 6% increase in price/mix, despite a 1% decline in global unit case volume. Coca-Cola maintained its full-year organic revenue growth guidance of 5% to 6% and adjusted free cash flow outlook of $9.5 billion. Keurig Dr Pepper also posted strong second-quarter results with adjusted EPS of $0.49 beating estimates, revenue of $4.16 billion, and net income of $547 million, driven by growth in U.S. Refreshment Beverages and energy and sports hydration segments.